Journey Medical Corporation (DERM) Reports Q3 Loss, Lags Revenue Estimates
Journey Medical (DERM) delivered earnings and revenue surprises of -12.50% and -0.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?